Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS FH: Mipomersen in Severe Heterozygous Familial Hypercholesterolemia
NCT01475825Phase 3Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Dec 2011
- Primary completion
- Dec 2015
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 30
01
Overview
A Phase 3 trial of mipomersen in heterozygous familial hypercholesterolemia (HeFH), sponsored by Kastle Therapeutics LLC. Started Dec 2011; status: completed.
02
Drugs
mipomersen
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01475825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01475825.